GlassScriptPhysician profile
Mcdavid M Mahaffey
NPI 1124163811
$9,429.34
in general payments reported to CMS, 2019-2025
65 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $571 · 2021: $1,105 · 2022: $1,916 · 2023: $1,697 · 2024: $1,910 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,912.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,171.29 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $906.93 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $822.80 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $663.68 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $513.19 | 2019-2025 | |
| Corium, LLC | $510.30 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $341.27 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $336.77 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $279.50 | 2020-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $279.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Supernus Pharmaceuticals, INC. | $252.99 | 2019-2025 | Qelbree, Xyosted |
| Tris Pharma INC | $244.97 | 2019-2024 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.06 | 2021-2025 | Xifaxan |
| Lundbeck LLC | $192.54 | 2022-2025 | Rexulti |
| Amarin Pharma, INC. | $154.58 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mcdavid Mahaffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.